

BEST AVAILABLE COPY

Attorney's Docket No.: 18202-020001/1088

OFFICIAL COMMUNICATION FACSIMILE:**OFFICIAL FAX NO: (571) 270-9945**

Number of pages including this page 11

Applicant : Lin Zhi et al.
 Serial No. : 10/684,229
 Filed : October 10, 2003
 Cust. No. : 20985

Art Unit : 1625
 Examiner : Charanjit Aulakh
 Patent No. : 7,071,205
 Issue Date : July 4, 2006

Title : 5-Cycloalkenyl 5H-Chromeno[3,4-f]Quinoline Derivatives as Selective
 Progesterone Receptor Modulator Compounds

Ms. Michelle Williams
 Certificate of Corrections Branch
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Ms. Williams:

Further to our telephone conversation on 8 February 2007, a hand-corrected version of the Certificate of Correction for the above captioned patent is attached. Please note the errors introduced by the PTO on the following pages:

On page 1, in the definition of R^1 , please replace " CO_2R^{11} , CO_2R^{11} " with $-\text{COR}^{11}$, CO_2R^{11} —

On page 8, in compound 73, please replace "cyclopentenyl" with —cyclopentenyl—

On page 9, in compound 85, please replace "difluoro" with —difluoro—

On page 9, in compound 87, please replace "cyclohexyl" with —cyclohexyl—

Patentee respectfully requests correction of these errors.

Respectfully submitted,

Date: February 8, 2007


 Nathanael R. Luman

Scientific Advisor to
 Stephanie Scidman
 Reg. No. 33,779

Fish & Richardson P.C.
 12390 El Camino Real
 San Diego, California 92130
 Telephone: (858) 678-4715
 Fax: (858) 678-5099
 email: luman@fr.com

NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at (858) 678-5070 to arrange for its return. Thank you.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2
 APPLICATION NO. : 10/684229
 DATED : July 4, 2006
 INVENTOR(S) : Lin Zhi et al.

Page 1 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE TITLE PAGES:

In Item [56] References Cited, in U.S. PATENT DOCUMENTS:

please add the following reference: --6,001,846 A 12/1999 Edwards et al. 514/285--
 in 6,566,358 please replace "Zhi et al." with --Zhang et al.--
 in 6,566,372 please replace "West et al." with --Zhi et al.--

In Item [56] References Cited, in OTHER PUBLICATIONS:


in Hamann et al., please replace "dihyrdo" with --dihydro--

At column 8, Table A, row R¹, please replace "C₁-C haloalkyl" with --C₁-C₄ haloalkyl--
 at column 9, Table A, row R⁹, please replace "CONR^HR¹²" with --CONR¹¹R¹²--
 at column 11, Table A, below row R¹⁶, please replace "R¹⁵" with --R¹⁶--

Please replace Claims 12, 13, 14, and 15 with the following Claims:

Col. 40

12. A compound of the formula:



(I)

wherein:

R¹ is selected from the group of hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ heteroalkyl, CO₂R¹¹, CO₂R¹¹, SO₂R¹¹, and CONR¹¹R¹²;
 R² and R³ each independently is selected from the group of hydrogen, C₁-C₄ alkyl, and C₁-C₄ haloalkyl; or
 R² and R³ taken together form a cycloalkyl ring of from three to twelve carbons;
 R⁴ through R⁷ each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR¹¹, C₁-C₄ alkyl, C₁-C₄ haloalkyl, and C₁-C₄ heteroalkyl; or
 R⁵ and R⁷ taken together form a bond; or
 R⁶ and R⁷ taken together are selected from the group of methyldene, mono-substituted methyldene, di-substituted methyldene and carbonyl;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2
 APPLICATION NO. : 10/684229
 DATED : July 4, 2006
 INVENTOR(S) : Lin Zhi et al.

Page 2 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R^2 through R^{10} each independently is selected from the group of hydrogen, F, Cl, Br, I, NO_2 , CN, OR^{11} , $\text{NR}^{11}\text{R}^{12}$, SR^{11} , COR^{11} , CO_2R^{11} , $\text{CONR}^{11}\text{R}^{12}$, $\text{C}_1\text{--C}_8$ alkyl, $\text{C}_1\text{--C}_8$ heteroalkyl, $\text{C}_1\text{--C}_8$ haloalkyl, allyl, $\text{C}_2\text{--C}_8$ alkenyl and $\text{C}_2\text{--C}_8$ alkynyl;

R^{11} and R^{12} each is independently selected from the group of hydrogen, $\text{C}_1\text{--C}_4$ alkyl, $\text{C}_1\text{--C}_4$ heteroalkyl, and $\text{C}_1\text{--C}_4$ haloalkyl;

R^{13} is hydrogen;

R^{14} and R^{16} taken together form a bond or "O-" bridge;

R^{15} , R^{17} , R^{18} , R^{19} , R^{20} each independently is selected from the group of hydrogen, F, Cl, $\text{C}_1\text{--C}_4$ alkyl, and $\text{C}_1\text{--C}_4$ haloalkyl;


R^{21} is hydrogen; and

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

Col. 41

13. A compound of the formula:



(1)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2
APPLICATION NO. : 10/684229
DATED : July 4, 2006
INVENTOR(S) : Lin Zhi et al.

Page 3 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

wherein:

R¹ is selected from the group of hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ heteroalkyl, COR¹¹, CO₂R¹¹, SO₂R¹¹, and CONR¹¹R¹²;

R² and R³ each independently is selected from the group of hydrogen, C₁-C₆ alkyl, and C₁-C₆ haloalkyl; or

R² and R³ taken together form a cycloalkyl ring of from three to twelve carbons;

R⁴ through R⁷ each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR¹¹, C₁-C₄ alkyl, C₁-C₄ haloalkyl, and C₁-C₄ heteroalkyl; or

R⁵ and R⁷ taken together form a bond; or

R⁶ and R⁷ taken together are selected from the group of methyldiene, mono-substituted methyldiene, di-substituted methyldiene and carbonyl;

R⁸ through R¹⁰ each independently is selected from the group of hydrogen, F, Cl, Br, I, NO₂, CN, OR¹¹, NR¹¹R¹², SR¹¹, COR¹¹, CO₂R¹¹, CONR¹¹R¹², C₁-C₈ alkyl, C₁-C₈ heteroalkyl, C₁-C₈ haloalkyl, allyl, C₂-C₈ alkenyl and C₂-C₈ alkynyl;

R¹¹ and R¹² each is independently selected from the group of hydrogen, C₁-C₄ alkyl, C₁-C₄ heteroalkyl, and C₁-C₄ haloalkyl;

R¹³ is hydrogen;

R¹⁴, R¹⁵, R¹⁸, R¹⁹, R²⁰ each independently is selected from the group of hydrogen, F, Cl, C₁-C₄ alkyl, and C₁-C₄ haloalkyl;

R¹⁶ and R¹⁷ taken together are selected from the group of methyldiene, mono-substituted methyldiene, and di-substituted methyldiene;

R²¹ is hydrogen; or

R²¹ and R²⁰ taken together form a bond;

n is 0, 1, 2, or 3;

or a pharmaceutically acceptable salt thereof.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 7,071,205 B2
 APPLICATION NO. : 10/684229
 DATED : July 4, 2006
 INVENTOR(S) : Lin Zhi et al.

Page 4 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 42

14. A compound of the formula:



(I)

wherein:

- R¹ is selected from the group of hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ heteroalkyl, COR¹¹, CO₂R¹¹, SO₂R¹¹, and CONR¹¹R¹²;
- R² and R³ each independently is selected from the group of hydrogen, C₁-C₆ alkyl, and C₁-C₆ haloalkyl; or
- R² and R³ taken together form a cycloalkyl ring of from three to twelve carbons;
- R⁴ through R⁷ each independently is selected from the group of hydrogen, F, Cl, Br, CN, OR¹¹, C₁-C₄ alkyl, C₁-C₄ haloalkyl, and C₁-C₄ heteroalkyl; or
- R⁵ and R⁷ taken together form a bond; or
- R⁶ and R⁷ taken together are selected from the group of methylenedene, mono-substituted methylenedene, di-substituted methylenedene and carbonyl;
- R⁸ through R¹⁰ each independently is selected from the group of hydrogen, F, Cl, Br, I, NO₂, CN, OR¹¹, NR¹¹R¹², SR¹¹, COR¹¹, CO₂R¹¹, CONR¹¹R¹², C₁-C₈ alkyl, C₁-C₈ heteroalkyl, C₁-C₈ haloalkyl, allyl, C₂-C₈ alkenyl and C₂-C₈ alkynyl;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2
APPLICATION NO. : 10/684,229
DATED : July 4, 2006
INVENTOR(S) : Lin Zhi et al.

Page 5 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below.

R¹¹ and R¹² each is independently selected from the group of hydrogen, C₁-C₄ alkyl, C₁-C₄ heteroalkyl, and C₁-C₄ haloalkyl;
R¹³ is hydrogen;
R¹⁴, R¹⁵, R¹⁷, R²⁰ each independently is selected from the group of hydrogen, F, Cl, C₁-C₄ alkyl, and C₁-C₄ haloalkyl;
R¹⁶ and R¹⁸ taken together form a bond when n is 1;
R¹⁶ and R¹⁹ taken together form a bond when n is 0;
R²¹ is hydrogen; and
n is 0, 1, 2, or 3;
or a pharmaceutically acceptable salt thereof.

Col. 42-45

15. A Compound selected from the group of:

(±)-(5¹,1¹)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 24);
(±)-(5¹,1^u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 25);
(+)-(5¹,1^l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 27);
(-)-(5¹,1^l)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 28);
(±)-(5¹,1^l)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 29);

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2
APPLICATION NO. : 10/684229
DATED : July 4, 2006
INVENTOR(S) : Lin Zhi et al.

Page 6 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 30);
- (+)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 32);
- (-)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-hydroxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 33);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 34);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 35);
- (+)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 37);
- (-)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 38);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 39);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 41);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2-dimethyl-5H-chromeno[3,4-f]quinoline (compound 42);
- (±)-(51,1'1)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 44);
- (±)-(51,1'u)-5-(3-methyl-2-cyclopentenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 45);

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2
APPLICATION NO. : 10/684229
DATED : July 4, 2006
INVENTOR(S) : Lin Zhi et al.

Page 7 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-(51,1'1)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 47);
- (±)-(51,1'u)-5-(3,5,5-trimethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 48);
- (±)-(51,1'1)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 50);
- (±)-(51,1'u)-5-(3-methyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 51);
- (±)-5-(3-methyl-3-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 52);
- (±)-5-(2-cyclopenta-1,3-dienyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 53);
- (±)-(51,1'1)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 55);
- (±)-(51,1'u)-5-(3-ethyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 56);
- (±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 58);
- (±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-7-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 59);
- (±)-(51,1'1)-5-(3-ethyl-2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 61);
- (±)-(51,1'1)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 62);

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2
APPLICATION NO. : 10/684229
DATED : July 4, 2006
INVENTOR(S) : Lin Zhi et al.

Page 8 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-(51,1'1)-5-(3-methyl-3-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 63);
(±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 64);
(±)-(51,1'u)-5-(3-methyl-2-cyclohexenyl)-9-fluoro-1,2-dihydro-8-methoxy-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 65);
(±)-(51,1'1)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 67);
(±)-(51,1'u)-5-(2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 68);
(±)-5-(1-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 69);
(±)-(51,1'1)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 71); ~~cyclopentenyl~~ → *cyclopentenyl*
(+)-(51,1'1)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 73);
(-)-(51,1'1)-5-(2,3-dimethyl-2-cyclopentenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 74);
(±)-(51,1'1)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 75);
(±)-(51,1'u)-5-(2-cyclohexenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 76);
(±)-(51,1'1)-5-(2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylidene-5H-chromeno[3,4-f]quinoline (compound 77);

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2
APPLICATION NO. : 10/684229
DATED : July 4, 2006
INVENTOR(S) : Lin Zhi et al.

Page 9 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- (±)-(51,1'1)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 79);
(±)-(51,1'u)-5-(2-methylidenecyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 80);
(±)-(51,1'1)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 81);
(±)-(51,1'u)-5-(2-oxocyclohexyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 82);
(±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-9-methoxy-1,2-dihydro-1,2,2,4-tetramethyl-5H-chromeno[3,4-f]quinoline (compound 83);
(±)-5-(2-cyclohexenyl)-9-fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 84);
(±)-(51,1'1)-5-(2,3-dimethyl-2-cyclohexenyl)-7,9-~~di~~^{di}fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 85);
(±)-5-(3-methylidene~~cyclohexyl~~)-7,9-~~di~~^{di}fluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 87); ~~cyclohexyl~~
(±)-(51,1'u)-5-(3-ethylidenecyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (compound 88);
(±)-(51,1'1)-5-(2-cycloheptenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 89);
(±)-(51,1'1)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 91);
(±)-(51,1'u)-5-(2-cyclooctenyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 92);

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,071,205 B2
APPLICATION NO. : 10/684229
DATED : July 4, 2006
INVENTOR(S) : Lin Zhi et al.

Page 10 of 10

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-(51,1'1)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 94);
(±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-4-methylene-5H-chromeno[3,4-f]quinolin-3-ol (Compound 95);
(±)-(51,1'1)-5-(2,3-epoxy-2,3-dimethylcyclopentyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 96);
(±)-(51,1'u)-5-(2,3-epoxy-3-methylcyclohexyl)-7,9-difluoro-1,2-dihydro-2,2,4-trimethyl-5H-chromeno[3,4-f]quinoline (Compound 97); and
(±)-(51,1'1)-5-(3-methyl-2-cyclohexenyl)-7,9-difluoro-1,2,3,4-tetrahydro-2,2-dimethyl-5H-chromeno[3,4-f]quinolin-4-one (Compound 98).

Signed and Sealed this

Twenty-eighth Day of November, 2006



JON W. DUDAS
Director of the United States Patent and Trademark Office

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.